Kelly P. McCarrier
Research Subjects
Kelly P. McCarrier has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Robert J. Wirth
Vector Psychometric Group
2 shared publications Alexandra L. Bryant
Vector Psychometric Group Chapel Hill North Carolina USA
1 shared publicationAstra M. Liepa
Eli Lilly and Company, Global Patient Outcomes and Real World Evidence, Indianapolis, Indiana
1 shared publication- Caroline Seo
BioPharmaceuticals Medical Evidence, AstraZeneca, Gaithersburg, USA
1 shared publication - Carrie R. Houts
Vector Psychometric Group Chapel Hill North Carolina USA
1 shared publication Dasha Cherepanov
Takeda Development Center Americas, Inc (TDCA)
1 shared publication
Latest Publications
- Open Access
- 18 January 2024
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 64 (2) , 156-171
The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine
Objective: To describe the impact of migraine on functioning based on comprehensive data collection, analysis, and reporting of patients' experiences. Background: Qualitative research conducted to understand patients' perspectives on living with migraine has often focused on narrow topics or specific groups of patients or has been selectively reported. Methods: Qualitative interviews with 71 participants were conducted during two concept elicitation studies as part of the Migraine Clinical Outcome Assessment System (MiCOAS) project, an FDA grant‐funded program designed to develop a core set of patient‐centered outcome measures for migraine clinical trials. Participants self‐reported being diagnosed with migraine by a healthcare professional and participated in semi‐structured qualitative interviews about their experiences with the symptoms and impacts of migraine. Interview transcripts were coded to identify and define concepts, which were then grouped into broad domains based on conceptual similarities. Results: A total of 66 concepts were identified: 12 for physical functioning, 16 for cognitive functioning, 10 for social role functioning, 19 for emotional and psychological functioning, and 9 related to migraine management. Participants described a complex and varied relationship between migraine attack symptoms and impacts on functioning. Impacts from migraine were further influenced by numerous contextual factors, such as people's individual social environments and the level of day‐to‐day demand for functioning they face. Conclusion: Findings showed that migraine impacted individual functioning in multiple ways and the nature of these impacts was dependent on social‐contextual factors. The results are being used in the development of core measures designed to improve our understanding of the burden of migraine and the efficacy of migraine therapies. The results also offer new insights and raise new questions about migraine experience that can be used to guide future research.
- 18 January 2024
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 64 (2) , 156-171
Open AccessThe impacts of migraine on functioning: Results from two qualitative studies of people living with migraine
Objective: To describe the impact of migraine on functioning based on comprehensive data collection, analysis, and reporting of patients' experiences. Background: Qualitative research conducted to understand patients' perspectives on living with migraine has often focused on narrow topics or specific groups of patients or has been selectively reported. Methods: Qualitative interviews with 71 participants were conducted during two concept elicitation studies as part of the Migraine Clinical Outcome Assessment System (MiCOAS) project, an FDA grant‐funded program designed to develop a core set of patient‐centered outcome measures for migraine clinical trials. Participants self‐reported being diagnosed with migraine by a healthcare professional and participated in semi‐structured qualitative interviews about their experiences with the symptoms and impacts of migraine. Interview transcripts were coded to identify and define concepts, which were then grouped into broad domains based on conceptual similarities. Results: A total of 66 concepts were identified: 12 for physical functioning, 16 for cognitive functioning, 10 for social role functioning, 19 for emotional and psychological functioning, and 9 related to migraine management. Participants described a complex and varied relationship between migraine attack symptoms and impacts on functioning. Impacts from migraine were further influenced by numerous contextual factors, such as people's individual social environments and the level of day‐to‐day demand for functioning they face. Conclusion: Findings showed that migraine impacted individual functioning in multiple ways and the nature of these impacts was dependent on social‐contextual factors. The results are being used in the development of core measures designed to improve our understanding of the burden of migraine and the efficacy of migraine therapies. The results also offer new insights and raise new questions about migraine experience that can be used to guide future research.
- Open Access
- 1 May 2022
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 237, 91-103
Development and Validation of a Visual Symptom–Specific Patient-Reported Outcomes Instrument for Adults With Cataract Intraocular Lens Implants
- 1 May 2022
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 237, 91-103
Open AccessDevelopment and Validation of a Visual Symptom–Specific Patient-Reported Outcomes Instrument for Adults With Cataract Intraocular Lens Implants
- Open Access
- 2 September 2021
- Published by Springer Nature in Research Square
Patient Perspectives on Symptoms, Health-Related Quality of Life, and Treatment Experience Associated with Relapsed/Refractory Multiple Myeloma
Purpose: This study aimed to better understand the patient perspective on relapsed and/or refractory multiple myeloma (RRMM) treatment.Methods: This non-interventional, cross-sectional study enrolled adult RRMM patients from 6 US clinics who had ≥3 months of life expectancy, ≤6 prior lines of therapy, and ≥1 treatment regimen with a proteasome inhibitor and immunomodulator, or a CD38 monoclonal antibody or an alkylating agent, and a steroid. In-person semi-structured qualitative interviews were conducted to capture concepts that were relevant and important to patients. Topics included RRMM symptoms and impacts and the mode of administration, frequency, duration, convenience, side effects, and overall experience with RRMM treatment.Results: Twenty-two patients completed interviews. At enrollment, 59.1% of participants were using regimens containing dexamethasone, 36.4% daratumumab, 27.3% carfilzomib, and 18.2% lenalidomide. More participants had experience using intravenous or injectable therapy alone (40.9%) than oral therapy alone (18.2%). Back pain and fatigue were the most frequently reported symptoms (40.9% each); 27.3% reported no symptoms. Most participants reported physical function limitations (86.4%), emotional impacts (77.3%), MM-related activity limitations (72.7%), and sleep disturbances (63.6%). Most participants perceived treatment effectiveness based on physician-explained clinical signs (68.2%) and symptom relief (40.9%). Participants experienced gastrointestinal side effects (59.1%), fatigue (59.1%), sleep disturbances (31.8%), and allergic reactions (31.8%) with treatment. Key elements of treatment burden included the duration of a typical treatment day (68.2%), treatment interfering with daily activities (54.5%), and infusion duration (50.0%).Conclusions: These results provide treatment experience–related data to further understand RRMM treatment burden and better inform treatment decision-making.
- 2 September 2021
- Published by Springer Nature in Research Square
Open AccessPatient Perspectives on Symptoms, Health-Related Quality of Life, and Treatment Experience Associated with Relapsed/Refractory Multiple Myeloma
Purpose: This study aimed to better understand the patient perspective on relapsed and/or refractory multiple myeloma (RRMM) treatment.Methods: This non-interventional, cross-sectional study enrolled adult RRMM patients from 6 US clinics who had ≥3 months of life expectancy, ≤6 prior lines of therapy, and ≥1 treatment regimen with a proteasome inhibitor and immunomodulator, or a CD38 monoclonal antibody or an alkylating agent, and a steroid. In-person semi-structured qualitative interviews were conducted to capture concepts that were relevant and important to patients. Topics included RRMM symptoms and impacts and the mode of administration, frequency, duration, convenience, side effects, and overall experience with RRMM treatment.Results: Twenty-two patients completed interviews. At enrollment, 59.1% of participants were using regimens containing dexamethasone, 36.4% daratumumab, 27.3% carfilzomib, and 18.2% lenalidomide. More participants had experience using intravenous or injectable therapy alone (40.9%) than oral therapy alone (18.2%). Back pain and fatigue were the most frequently reported symptoms (40.9% each); 27.3% reported no symptoms. Most participants reported physical function limitations (86.4%), emotional impacts (77.3%), MM-related activity limitations (72.7%), and sleep disturbances (63.6%). Most participants perceived treatment effectiveness based on physician-explained clinical signs (68.2%) and symptom relief (40.9%). Participants experienced gastrointestinal side effects (59.1%), fatigue (59.1%), sleep disturbances (31.8%), and allergic reactions (31.8%) with treatment. Key elements of treatment burden included the duration of a typical treatment day (68.2%), treatment interfering with daily activities (54.5%), and infusion duration (50.0%).Conclusions: These results provide treatment experience–related data to further understand RRMM treatment burden and better inform treatment decision-making.
- Open Access
- 26 August 2021
- Published by Elsevier in Current Therapeutic Research
- Vol. 95, 100642
Non–Small Cell Lung Cancer Symptom Assessment Questionnaire: Psychometric Performance and Regulatory Qualification of a Novel Patient-Reported Symptom Measure
- 26 August 2021
- Published by Elsevier in Current Therapeutic Research
- Vol. 95, 100642
Open AccessNon–Small Cell Lung Cancer Symptom Assessment Questionnaire: Psychometric Performance and Regulatory Qualification of a Novel Patient-Reported Symptom Measure